Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization


China NMPA approval based on...

Related Keywords

Japan , Macau , Laos , Philippines , Hong Kong , Cambodia , Taiwan , New Zealand , Vietnam , Republic Of , Indonesia , Australia , Thailand , United States , Singapore , China , Malaysia , Chinese , Harald Reinhart , Matt Ronsheim , Acinetobacter Baumannii , Centers For Disease , Head Of Global Development , Zai Lab Limited , Zai Lab , Securities Exchange , Innoviva Inc , Drug Administration , Zai Lab Forward , Exchange Commission , Jolla Pharmaceutical Company , Entasis Therapeutics Inc , Zai Lab New Drug Application , World Health Organization , China National Medical Products Administration , Innoviva Specialty Therapeutics , National Medical Products Administration , New Drug Application , Global Development , Infectious Diseases , Innoviva Specialty , Greater China , Disease Control , Acinetobacter Baumannii Infections , Full Prescribing Information , Private Securities Litigation Reform Act , Specialty Therapeutics , Specialty Therapeutic , Securities Exchange Act , Financial Condition , Annual Report , Quarterly Reports , Risk Factors , Clinical Presentation , Molecular Bacterial Pathogenesis Volume , Antimicrobial Resistance , Rev Drug , Antibiotic Resistance , Patient Safety , China Diagnosis , Treatment Guideline ,